Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 125, Issue 1, 2015, Pages 183-190

  Thomas, Alissa A ^a   Arevalo Perez, Julio ^a   Kaley, Thomas ^a   Lyo, John ^a   Peck, Kyung K ^a   Shi, Weiji ^a   Zhang, Zhigang ^a   Young, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

DCE MRI; Glioblastoma; Perfusion; Pseudoprogression

Indexed keywords

TEMOZOLOMIDE; ALKALOID; ALKYLATING AGENT; CONTRAST MEDIUM; DACARBAZINE; WILCOX COMPOUND;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA VOLUME; RANK SUM TEST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; VERY ELDERLY; VOLUMETRY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ALKALOIDS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CONTRAST MEDIA; DACARBAZINE; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942988247     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1893-z     Document Type: Article

References (23)

1. Rogers LR (2012) Neurologic complications of radiation. Continuum 18(2):343–354. doi:10.1212/01.CON.0000413662.35174.a8
2. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461. doi:10.1016/S1470-2045(08)70125-6
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
4. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. doi:10.1200/JCO.2009.26.3541
5. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197. doi:10.1200/JCO.2007.14.8163
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi:10.1056/NEJMoa043331
7. Tran DK, Jensen RL (2013) Treatment-related brain tumor imaging changes: so-called “pseudoprogression” vs. tumor progression: review and future research opportunities. Surg Neurol Int 4(Suppl 3):S129–S135. doi:10.4103/2152-7806.110661
8. Viallon M, Cuvinciuc V, Delattre B, Merlini L, Barnaure-Nachbar I, Toso-Patel S, Becker M, Lovblad KO, Haller S (2015) State-of-the-art MRI techniques in neuroradiology: principles, pitfalls, and clinical applications. Neuroradiology 57(5):441–467. doi:10.1007/s00234-015-1500-1
9. Yeo DM, Oh SN, Jung CK, Lee MA, Oh ST, Rha SE, Jung SE, Byun JY, Gall P, Son Y, Son Y (2013) Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: preliminary results. J Magn Reson Imaging: JMRI 41:474–480. doi:10.1002/jmri.24541
10. Chung WJ, Kim HS, Kim N, Choi CG, Kim SJ (2013) Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. Radiology 269(2):561–568. doi:10.1148/radiol.13130016
11. Jung SC, Yeom JA, Kim JH, Ryoo I, Kim SC, Shin H, Lee AL, Yun TJ, Park CK, Sohn CH, Park SH, Choi SH (2014) Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 35(6):1103–1110. doi:10.3174/ajnr.A3825
12. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging: JMRI 10(3):223–232
13. Hopewell JW, Calvo W, Jaenke R, Reinhold HS, Robbins ME, Whitehouse EM (1993) Microvasculature and radiation damage. Recent Results Cancer Res 130:1–16
14. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, Holodny AI, Omuro AM (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76(22):1918–1924. doi:10.1212/WNL.0b013e31821d74e7
15. Nasseri M, Gahramanov S, Netto JP, Fu R, Muldoon LL, Varallyay C, Hamilton BE, Neuwelt EA (2014) Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro-oncology 16(8):1146–1154. doi:10.1093/neuonc/not328
16. Song YS, Choi SH, Park CK, Yi KS, Lee WJ, Yun TJ, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Jahng GH, Chang KH (2013) True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean J Radiol 14(4):662–672. doi:10.3348/kjr.2013.14.4.662
17. Sourbron S, Ingrisch M, Siefert A, Reiser M, Herrmann K (2009) Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med 62(1):205–217. doi:10.1002/mrm.22005
18. Yun TJ, Park CK, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Choi SH (2015) Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology 274(3):830–840. doi:10.1148/radiol.14132632
19. Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H (2014) Longitudinal DSC-MRI for distinguishing tumor recurrence from pseudoprogression in patients with a high-grade glioma. Am J Clin Oncol. doi:10.1097/COC.0000000000000156
20. Arvinda HR, Kesavadas C, Sarma PS, Thomas B, Radhakrishnan VV, Gupta AK, Kapilamoorthy TR, Nair S (2009) Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 94(1):87–96. doi:10.1007/s11060-009-9807-6
21. Linhares P, Carvalho B, Figueiredo R, Reis RM, Vaz R (2013) Early pseudoprogression following chemoradiotherapy in glioblastoma patients: the value of RANO evaluation. J Oncol 2013:690585. doi:10.1155/2013/690585
22. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2):405–410. doi:10.1002/cncr.23562
23. Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, Lam K, Davey P, Tsao MN (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37(1):36–42